News Center
2026-10-27
Recently, Xiamen Winbio Biotechnology Co., Ltd. successfully passed the certification and was recognized as a national high-tech enterprise. Founded in 2017, the company is based in the Haicang Biopharmaceutical Industrial Park and is also designated as a specialized, refined, distinctive, and innovative enterprise in Xiamen. This dual accreditation represents an authoritative endorsement of the company’s R&D innovation capabilities and its level of industrialization.
2026-10-27
Xiamen Winbio Biotechnology Co., Ltd. has been recognized as a “Specialized, Refined, Distinctive, and Innovative” enterprise in Xiamen, thanks to its meticulous expertise in the field of in vitro diagnostic active raw materials. Established in 2017 within the Haicang Biopharmaceutical Industrial Park, the company also holds national-level high-tech enterprise certification and focuses on the research and development, manufacturing, and technical services of core upstream raw materials.
2026-10-27
In vitro diagnostic raw materials are the “chips” of the industry, and achieving independent control over upstream supplies is pivotal for sector development. Established in 2017, Xiamen Winbio Biotechnology Co., Ltd. is headquartered in the Haicang Biomedical Industrial Park. As a national-level high-tech enterprise and a specialized, refined, distinctive, and innovative company in Xiamen, it focuses on the R&D and production of active raw materials such as antigens, antibodies, and recombinant proteins.
2026-10-27
Xiamen Winbio Biotechnology Co., Ltd., leveraging a mature R&D platform, offers antigen, antibody, and recombinant protein active raw materials—along with tailored solutions—compatible with multiple technological platforms for in vitro diagnostic customers. Founded in 2017 and located in the Haicang Biomedical Industrial Park, the company is a national-level high-tech enterprise and a specialized, refined, distinctive, and innovative enterprise recognized by Xiamen City. Winbio Biotechnology boasts a comprehensive product portfolio, supporting the development of mainstream IVD platforms, including chemiluminescence, ELISA, fluorescence immunoassay, and colloidal gold rapid tests. Different assay platforms have distinct requirements for raw material labeling performance, specificity, and stability. The company’s core team comprises seasoned experts with over 30 years of experience and key technical leaders from across the industry chain, enabling targeted optimization of raw materials to suit specific platform characteristics and providing accompanying application‑process guidance. From recombinant protein expression and antigen–antibody preparation to raw material performance validation and platform‑specific tuning, Winbio Biotechnology has established end-to-end service capabilities, offering one-stop support for reagent manufacturers’ multi‑pipeline development and delivering reliable raw material supplies for the creation of diverse in vitro diagnostic products.
2026-10-27
Recombinant proteins are the foundational raw materials for the development of in vitro diagnostic reagents. Xiamen Winbio Biotechnology Co., Ltd. focuses on the research and development and large-scale production of recombinant proteins, providing IVD industry customers with high-quality, bioactive raw materials and tailored application solutions. Founded in 2017 in the Haicang Biomedical Industrial Park, the company is a national-level high-tech enterprise and a specialized, refined, distinctive, and innovative enterprise recognized by Xiamen City.
2026-10-27
Antibodies are the core functional reagents in immunoassay diagnostics, directly determining assay sensitivity and specificity. Xiamen Winbio Biotechnology Co., Ltd. specializes in the research, development, and production of high‑quality diagnostic antibodies, providing in vitro diagnostic companies with stable, reliable antibody raw materials and comprehensive technical solutions.